Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Source: View publication →
The MATRIX trial demonstrated that radial access significantly reduces net adverse clinical events compared to femoral access in patients with acute coronary syndromes, while bivalirudin provided no significant benefit over unfractionated heparin regarding major ischemic or net adverse events.
Key Findings
Study Design
Study Limitations
Clinical Significance
The MATRIX trial supports the transition toward radial access as the standard of care for patients with acute coronary syndrome undergoing invasive management due to its clear benefits in reducing bleeding and net adverse clinical events. Conversely, the results for bivalirudin suggest it does not offer a clear superiority over unfractionated heparin in preventing major ischemic events, reinforcing the need for individualized antithrombotic therapy.
Historical Context
Prior to MATRIX, trials like RIVAL had suggested benefits for radial access in high-risk patients, but evidence remained debated. MATRIX was designed as a large-scale, 2x2 factorial study to definitively compare both access sites and antithrombotic strategies (bivalirudin vs. heparin) across the full spectrum of ACS, influencing global practice guidelines and cementing the radial-first approach.
Guided Discussion
High-yield insights from every perspective
Anatomically and physiologically, why does choosing the radial artery over the femoral artery as an access point for cardiac catheterization lead to a significant reduction in major bleeding complications?
Key Response
The radial artery is superficial and lies directly over the distal radius bone, making it easily compressible to achieve hemostasis. In contrast, the femoral artery is deeper and lacks a hard underlying structure for effective compression, increasing the risk of occult retroperitoneal hemorrhage or large hematomas which can lead to hemodynamic instability.
In the context of the MATRIX trial results, if a patient with ACS is undergoing PCI via radial access, does the evidence support the routine use of bivalirudin over unfractionated heparin (UFH) to reduce net adverse clinical events (NACE)?
Key Response
No. The MATRIX trial found that bivalirudin did not significantly reduce NACE or MACE compared to UFH. The previously observed benefits of bivalirudin in earlier trials were largely driven by a reduction in bleeding, which is already significantly minimized when using radial access. Therefore, UFH remains a standard, cost-effective choice in radial-first centers.
The MATRIX trial observed a reduction in all-cause mortality in the radial access group. Critically analyze whether this mortality benefit is solely attributable to reduced bleeding or if other factors like 'radial expertise' and crossover rates play a confounding role.
Key Response
While reduced bleeding is the primary mediator of the mortality benefit, the trial also reflects high operator proficiency. A high crossover rate from radial to femoral (often due to radial artery spasm or tortuosity) can dilute the 'intention-to-treat' benefit. The mortality benefit suggests that preventing even non-fatal major bleeds avoids the subsequent inflammatory cascade and cessation of antiplatelet therapy that often follows hemorrhagic events in ACS.
Given the results of MATRIX, how should we approach the 'radial-to-femoral' transition in complex cases? Does the trial suggest that the benefits of radial access are robust enough to justify longer procedure times in the setting of acute STEMI?
Key Response
The trial supports a 'radial-first' approach as the default, but clinician judgment is required. In STEMI, 'time is muscle,' and while radial access reduces mortality through bleeding avoidance, excessive attempts at radial access that delay reperfusion can be detrimental. The MATRIX results should be taught as a mandate for radial proficiency, but with a low threshold for femoral transition if the radial approach significantly delays the primary goal of vessel patency.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Evaluate the 2x2 factorial design of the MATRIX trial. How does the potential interaction between the access site intervention and the anticoagulation intervention affect the statistical power to detect a difference in the bivalirudin arm?
Key Response
In a factorial design, if one intervention (radial access) drastically reduces the event rate (bleeding) that the second intervention (bivalirudin) is designed to target, the trial may become underpowered to show a treatment effect for the second intervention (a 'floor effect'). This interaction suggests that the utility of bivalirudin is conditional upon the baseline bleeding risk inherent to the access site.
As a reviewer, how would you address the open-label design of the access-site randomization in MATRIX, specifically regarding the potential for 'ascertainment bias' in the reporting of bleeding events?
Key Response
Open-label trials are vulnerable to bias where investigators may more diligently search for or report complications in the 'control' (femoral) arm. To mitigate this, a tough reviewer would look for blinded adjudication of endpoints by an independent committee (which MATRIX used) and evaluate if the bleeding definitions used (e.g., BARC) are objective enough to minimize subjective interpretation by unblinded site investigators.
Based on the 1-year MATRIX data, should the preference for radial access be elevated to a Class I, Level A recommendation in ACS guidelines, and how does this affect the current ESC/ACC recommendations for bivalirudin?
Key Response
The MATRIX trial provides definitive evidence supporting radial access as the superior strategy for reducing NACE and mortality in ACS, justifying a Class I recommendation (as seen in ESC 2017/2020). Conversely, it supports downgrading the routine use of bivalirudin to a Class IIa or IIb, suggesting it should be reserved for patients with high bleeding risk or heparin-induced thrombocytopenia, rather than being the default over UFH.
Clinical Landscape
Noteworthy Related Trials
ACUITY Trial
Tested
Bivalirudin alone or bivalirudin plus glycoprotein IIb/IIIa inhibitors
Population
Patients with moderate-to-high-risk acute coronary syndromes
Comparator
Heparin plus glycoprotein IIb/IIIa inhibitors
Endpoint
Composite of death, myocardial infarction, or unplanned revascularization
HORIZONS-AMI Trial
Tested
Bivalirudin monotherapy
Population
Patients with ST-segment elevation myocardial infarction
Comparator
Heparin plus glycoprotein IIb/IIIa inhibitor
Endpoint
Major adverse cardiac events and major bleeding at 30 days
RIVAL Trial
Tested
Radial artery access
Population
Patients with acute coronary syndrome
Comparator
Femoral artery access
Endpoint
Composite of death, myocardial infarction, stroke, or non-procedure-related major bleeding at 30 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis